Patents by Inventor Deborah A. Moore
Deborah A. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11866476Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: GrantFiled: December 28, 2022Date of Patent: January 9, 2024Assignee: Xilio Development, Inc.Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
-
Patent number: 11827686Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: GrantFiled: June 4, 2021Date of Patent: November 28, 2023Assignee: Xilio Development, Inc.Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Singh Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
-
Patent number: 11827685Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: GrantFiled: June 4, 2021Date of Patent: November 28, 2023Assignee: Xilio Development, Inc.Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Singh Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
-
Patent number: 11718655Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: GrantFiled: April 8, 2022Date of Patent: August 8, 2023Assignee: XILIO DEVELOPMENT, INC.Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
-
Publication number: 20230235006Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: ApplicationFiled: December 28, 2022Publication date: July 27, 2023Applicant: Xilio Development, Inc.Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
-
Publication number: 20230135462Abstract: Cyanoacrylate compositions are provided, which when cured provide improved hot strength performance without compromising thermal resistance performance.Type: ApplicationFiled: December 22, 2022Publication date: May 4, 2023Inventors: Tammy Gernon, Michael Jordan, Susan Reilly, Martin Smyth, Deborah Moore, Patricia Hedderman, Aine Mooney
-
Publication number: 20230034325Abstract: A container for curable cyanoacrylate composition comprising: a reservoir for holding curable cyanoacrylate composition, the reservoir having an outlet through which the curable cyanoacrylate composition can be dispensed; the reservoir being defined by walls of plastics material, the plastics material being formed by a polymer material that is transmissive to both visible light and UV light; and a UV blocking agent dispersed in the plastics material the UV blocking agent comprising at least one benzotriazole; the walls of the container being transmissive to visible light and non-transmissive to UV light. Curable cyanoacrylate compositions held within such a container are thus storage stable in ambient conditions and yet the curable cyanoacrylate compositions can be seen through the walls of the container. A pack comprising the container and a curable cyanoacrylate composition is also described.Type: ApplicationFiled: June 20, 2022Publication date: February 2, 2023Inventors: Aine Mooney, Tammy Gernon, Susan Reilly, Martin Smyth, Deborah Moore, Michael Jordan, Patricia Hedderman, Bryan Brady, Lydie Coulombel, Henry Loughrey
-
Publication number: 20230030037Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: ApplicationFiled: June 4, 2021Publication date: February 2, 2023Applicants: Xilio Development, Inc., Xilio Development, Inc.Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj Singh TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
-
Publication number: 20230028959Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: ApplicationFiled: June 4, 2021Publication date: January 26, 2023Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj Singh TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
-
Publication number: 20220306716Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: ApplicationFiled: April 8, 2022Publication date: September 29, 2022Applicant: Xilio Development, Inc.Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
-
Publication number: 20220002370Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e.g., masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: ApplicationFiled: September 27, 2019Publication date: January 6, 2022Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
-
Publication number: 20210395571Abstract: Two-part cyanoacrylate/cationically curable adhesive systems, are provided.Type: ApplicationFiled: September 3, 2021Publication date: December 23, 2021Inventors: Aine Mooney, Susan Reilly, Deborah Moore
-
Patent number: 11053294Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: GrantFiled: August 25, 2020Date of Patent: July 6, 2021Assignee: Xilio Development, Inc.Inventors: Margaret Karow, Deborah Moore Lai, Dheeraj Singh Tomar, Parker Johnson, Raphael Rozenfeld, Ronan O'Hagan, Huawei Qiu
-
Publication number: 20210002343Abstract: Provided herein are cytokines or functional fragments thereof that, in some embodiments, are engineered to be masked by a masking moiety at one or more receptor binding site(s) of the cytokine or functional fragment thereof. In some embodiments, the cytokines are engineered to be activatable by a protease at a target site, such as in a tumor microenvironment, by including a proteolytically cleavable linker. In some embodiments, the proteolytically cleavable linker links the cytokine to the masking moiety, links the cytokine to a half-life extension domain, and/or links the masking moiety to a half-life extension domain. The masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavable linker at the target site, the cytokine becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.Type: ApplicationFiled: August 25, 2020Publication date: January 7, 2021Inventors: Margaret KAROW, Deborah Moore LAI, Dheeraj Singh TOMAR, Parker JOHNSON, Raphael ROZENFELD, Ronan O'HAGAN, Huawei QIU
-
Publication number: 20160128391Abstract: A side opening garment having a side opening for use in allowing the user to put on the garment using only one hand. The garment comprises a shirt having an upper end, an open lower end, and a pair of sleeves. A side of the body includes an opening extending from the lower end of the garment upward toward the sleeve, and along the underside of the sleeve. The opening can be positioned on the left side or right side of the shirt, depending upon the embodiment. A first edge of the opening and a second edge of the opening include fasteners thereon that can be removably secured to seal the opening. In this way, the garment allows a user to put on one side of the shirt in the conventional manner, while adorning the opposing side of the shirt by sealing the opening.Type: ApplicationFiled: November 10, 2015Publication date: May 12, 2016Inventor: Deborah Moore
-
Patent number: 9120957Abstract: Cyanoacrylate-containing compositions that include, in addition to the cyanoacrylate component, a hydrogenated anhydride and optionally a benzonitrile, are provided. Cured products of the inventive cyanoacrylate compositions demonstrate improved heat resistance without compromising fixture time, stability or color.Type: GrantFiled: January 14, 2014Date of Patent: September 1, 2015Assignee: Henkel IP & Holding GmbHInventors: Patricia A. Hedderman, Emer Ward, William Hally, Deborah A. Moore, Cormac Duffy, Marisa Phelan
-
Patent number: 8981027Abstract: Two part cyanoacrylate/cationically curable adhesive systems are provided.Type: GrantFiled: March 15, 2013Date of Patent: March 17, 2015Assignee: Henkel IP & Holding GmbHInventors: Emer Ward, Susan Reilly, Patricia A. Hedderman, Rachel Hersee, Deborah A. Moore
-
Patent number: 8933168Abstract: There is provided a cyanoacrylate composition comprising: a cyanoacrylate; and a 2-substituted benzothiazole or a derivative thereof wherein the 2-substituent is an alkyl, an alkene, an alkylbenzyl, an alkylamino, an alkoxy, an alkylhydroxy, an ether, a sulfenamide, a thioalkyl or a thioalkoxy group, with the proviso that an amide portion of the sulfenamide does not have a tert butylamino or a morpholine group.Type: GrantFiled: April 20, 2011Date of Patent: January 13, 2015Assignee: Henkel IP & Holding GmbHInventors: William Hally, Emer Ward, Patricia A. Hedderman, Deborah A. Moore, Dermot F. Heatley
-
Publication number: 20140275419Abstract: Two part cyanoacrylate/cationically curable adhesive systems are provided.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: Henkel Ireland LimitedInventors: Emer Ward, Susan Reilly, Patricia A. Hedderman, Rachel Hersee, Deborah A. Moore
-
Publication number: 20140124137Abstract: Cyanoacrylate-containing compositions that include, in addition to the cyanoacrylate component, a hydrogenated anhydride and optionally a benzonitrile, are provided. Cured products of the inventive cyanoacrylate compositions demonstrate improved heat resistance without compromising fixture time, stability or color.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: Henkel lP & Holding GmbHInventors: Patricia A. Hedderman, Emer Ward, William Hally, Deborah A. Moore, Cormac Duffy, Marisa Phelan